Bayer's recent performance has had a mixed effect on its stocks. Following a period of continuous losses, analysts predict a 40% rebound. Driven by positive news in the medical sector, such as the
UK's nod for hot flash therapy and positive results in a pivotal cancer trial, speculators see Bayer as a
value and
buy stock.
Goldman Sachs and BofA Securities upgraded the German pharmaceutical giant's rating due to perceived
upside potential and
positive catalysts. However, it's not all good news.
Bayer’s Roundup litigation has sought review from the
US Supreme Court and a
$2B fine in a recent case sent stocks plunging. Warnings of a
2025 earnings fall caused a temporary decline too. Despite a
Q4 loss, growth views for FY26 resulted in a positive stock turn but the regulatory approval for its cancer drug only resulted in a transient uplift. A rise in stock is also observed after beating Q1 earnings estimates, despite losses in the crop science unit. Bayer's shares remain volatile with the upsides and downsides of Pharma and litigation collectively shaping its outlook.
BAYER Stocks News Analytics from Wed, 09 Oct 2024 07:00:00 GMT to Fri, 11 Jul 2025 15:12:54 GMT -
Rating 0
- Innovation 5
- Information 6
- Rumor -5
